Winners and Losers in Biopharma’s Q1 2024 Earnings Season

Skyrocketing weight-loss drug sales characterized the first quarter of 2024, with some companies beating Wall Street analysts’ earnings estimates, giving a clue to the current business environment and where things might be headed during the rest of the year for the biopharma industry. While Q1 was a generally positive quarter with some notable standout performers, it also featured companies struggling with patent cliffs and falling revenue.